These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35499850)

  • 61. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Applying the ILAE diagnostic criteria for Lennox-Gastaut syndrome in the real-world setting: A multicenter retrospective cohort study.
    Nightscales R; Chen Z; Barnard S; Auvrez C; Tao G; Sivathamboo S; Bennett C; Rychkova M; D'Souza W; Berkovic SF; Nicolo JP; O'Brien TJ; Perucca P; Scheffer IE; Kwan P
    Epilepsia Open; 2024 Apr; 9(2):602-612. PubMed ID: 38135919
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
    Chung SS; French JA; Kowalski J; Krauss GL; Lee SK; Maciejowski M; Rosenfeld WE; Sperling MR; Mizne S; Kamin M
    Neurology; 2020 Jun; 94(22):e2311-e2322. PubMed ID: 32409485
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
    Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
    Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures.
    Abou-Khalil B; Wheless J; Rogin J; Wolter KD; Pixton GC; Shukla RB; Sherman NA; Sommerville K; Goli V; Roland CL
    Epilepsia; 2013 Nov; 54(11):1968-76. PubMed ID: 24111974
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome.
    Kim HJ; Kim SH; Kang HC; Lee JS; Chung HJ; Kim HD
    Pediatr Neurol; 2014 Oct; 51(4):527-31. PubMed ID: 25266616
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The pharmacological management of Lennox-Gastaut syndrome and critical literature review.
    Verrotti A; Striano P; Iapadre G; Zagaroli L; Bonanni P; Coppola G; Elia M; Mecarelli O; Franzoni E; Liso P; Vigevano F; Curatolo P
    Seizure; 2018 Dec; 63():17-25. PubMed ID: 30391662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
    Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
    Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy.
    Sullivan J; Gunning B; Zafar M; Guerrini R; Gecz J; Kolc KL; Zhao Y; Gasior M; Aimetti AA; Samanta D
    Epilepsy Res; 2023 Mar; 191():107112. PubMed ID: 36870093
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
    Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F
    Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
    Balagura G; Cacciatore M; Grasso EA; Striano P; Verrotti A
    CNS Drugs; 2020 Oct; 34(10):1001-1007. PubMed ID: 32875491
    [TBL] [Abstract][Full Text] [Related]  

  • 78. DBS of Thalamic Centromedian Nucleus for Lennox-Gastaut Syndrome (ESTEL Trial).
    Dalic LJ; Warren AEL; Bulluss KJ; Thevathasan W; Roten A; Churilov L; Archer JS
    Ann Neurol; 2022 Feb; 91(2):253-267. PubMed ID: 34877694
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
    Felbamate Study Group in Lennox-Gastaut Syndrome
    N Engl J Med; 1993 Jan; 328(1):29-33. PubMed ID: 8347179
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome.
    Grosso S; Coppola G; Cusmai R; Parisi P; Spalice A; Foligno S; Verrotti A; Balestri P
    Acta Neurol Scand; 2014 Jun; 129(6):420-4. PubMed ID: 24479878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.